Online inquiry

IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3543MR)

This product GTTS-WQ3543MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MIF gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002415.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4282
UniProt ID P14174
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3543MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8756MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ6868MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ8633MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ12875MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15327MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ8501MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ15745MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ9155MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW